Floatz logo

55 assets in Cardiovascular Disorder

Therapeutic assets addressing Cardiovascular Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Atorvastatin
Cardiovascular Disorder
Duke UniversityP4BBB (76)
Liraglutide
Cardiovascular Disorder
University of Sao Paulo General HospitalP4BBB (76)
Rosuvastatin
Cardiovascular Disorder
Nanjing First Hospital, Nanjing Medical UniversityP4BBB (75)
Simvastatin
Cardiovascular Disorder
McMaster UniversityP4BBB (74)
Ramifentanyl
Cardiovascular Disorder
Helse FonnaP4BBB (73)
Noradrenaline
Cardiovascular Disorder
Helse FonnaP4BB (69)
Propofol
Cardiovascular Disorder
Helse FonnaP4BB (69)
Ephedrine, Anhydrous
Cardiovascular Disorder
Helse FonnaP4BB (68)
Warfarin
Cardiovascular Disorder
Seoul National University HospitalP4BB (68)
Pravastatin
Cardiovascular Disorder
McMaster UniversityP4BB (67)
Rivaroxaban
Cardiovascular Disorder
China National Center for Cardiovascular DiseasesP4BB (67)
Sitagliptin
Cardiovascular Disorder
Brigham and Women's HospitalP3BB (66)
Herpes Zoster Vaccine Gsk1437173A
Cardiovascular Disorder
Tor Biering-SørensenP4BB (65)
Semaglutide
Cardiovascular Disorder
Noom Inc.P4BB (65)
Metformin
Cardiovascular Disorder
The University of Texas Health Science Center at San AntonioP3BB (64)
Evolocumab
Cardiovascular Disorder
AmgenP4B (63)
Envarsus Product
Cardiovascular Disorder
University of AlbertaP4B (62)
Epclusa
Cardiovascular Disorder
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)P4B (62)
Ezetimibe
Cardiovascular Disorder
Seoul National University HospitalP3B (62)
Valsartan
Cardiovascular Disorder
University of Alabama at BirminghamP3B (62)
Acoramidis
Cardiovascular Disorder
Eidos Therapeutics, a BridgeBio companyP3B (60)
Apixaban
Cardiovascular Disorder
Region StockholmP3B (60)
Cilostazol
Cardiovascular Disorder
Stanford UniversityP3B (60)
Orforglipron
Cardiovascular Disorder
Eli Lilly and CompanyP3B (60)
tqj230
Cardiovascular Disorder
Novartis PharmaceuticalsP3B (60)
Isis-681257 (Galnac3--Conjugated Aso Targeting Human Lipoprotein (A) )
Cardiovascular Disorder
Novartis PharmaceuticalsP3B (59)
Retatrutide
Cardiovascular Disorder
Eli Lilly and CompanyP3B (57)
Sacubitril Valsartan
Cardiovascular Disorder
University of Alabama at BirminghamP2/3CCC (55)
AIR
Cardiovascular Disorder
Turku University HospitalP2CCC (53)
Apsolol
Cardiovascular Disorder
Tianjin Medical University General HospitalP2CCC (53)
Bempedoic Acid
Cardiovascular Disorder
Priscilla Hsue, MDP2CCC (53)
Ceftriaxone
Cardiovascular Disorder
Tianjin Medical University General HospitalP2CCC (53)
Oxygen
Cardiovascular Disorder
Turku University HospitalP2CCC (53)
Tirzepatide
Cardiovascular Disorder
Noom Inc.P2CCC (53)
Vericiguat
Cardiovascular Disorder
University of Alabama at BirminghamP2CCC (53)
XENON
Cardiovascular Disorder
Turku University HospitalP2CCC (53)
Pyruvate
Cardiovascular Disorder
National Heart Centre SingaporeP2CCC (49)
Human Relaxin 1
Cardiovascular Disorder
Deeptankar DeMazumderP1/2CCC (48)
Primepro™/ Primemsk™
Cardiovascular Disorder
Thomas Advanced Medical LLCP1/2CCC (48)
nt-0796
Cardiovascular Disorder
NodThera LimitedP1CC (44)
Actos
Cardiovascular Disorder
The University of Texas Health Science Center at San AntonioP1CC (41)
Empagliflozin
Cardiovascular Disorder
The University of Texas Health Science Center at San AntonioP1CC (41)
Gly-Low
Cardiovascular Disorder
Hoskinson Health and Wellness ClinicEarly P1CC (41)
Oricar-017
Cardiovascular Disorder
OriCell Therapeutics Co., Ltd.P1CC (41)
Rybelsus
Cardiovascular Disorder
The University of Texas Health Science Center at San AntonioP1CC (41)
Labetalol
Cardiovascular Disorder
Universitas Sumatera UtaraN/AD (30)
Lac Vaccinum
Cardiovascular Disorder
University of TorontoN/AD (30)
Showing 1 to 50 of 55 assets
PreviousPage 1 of 2Next